Other equities research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of NOVOZYMES A/S/S from a sell rating to a hold rating in a research report on Tuesday, November 20th. JPMorgan Chase & Co. upgraded shares of NOVOZYMES A/S/S from an underweight rating to a neutral rating in a research report on Wednesday, January 30th. Finally, Goldman Sachs Group upgraded shares of NOVOZYMES A/S/S from a sell rating to a neutral rating in a research report on Monday, January 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. NOVOZYMES A/S/S has a consensus rating of Hold.
OTCMKTS:NVZMY traded down $0.09 during mid-day trading on Tuesday, hitting $45.27. 11,645 shares of the company’s stock were exchanged, compared to its average volume of 58,541. NOVOZYMES A/S/S has a fifty-two week low of $40.38 and a fifty-two week high of $55.84. The company has a market cap of $13.73 billion, a PE ratio of 25.87, a P/E/G ratio of 2.29 and a beta of 0.84.
The business also recently disclosed an annual dividend, which will be paid on Tuesday, March 19th. Stockholders of record on Friday, March 1st will be paid a $0.504 dividend. The ex-dividend date is Thursday, February 28th. This represents a dividend yield of 1.16%. NOVOZYMES A/S/S’s dividend payout ratio is currently 28.00%.
About NOVOZYMES A/S/S
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. The company offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products.
Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.